Overview

• Wound care firm's Q4 net sales grew 27% yr/yr, beating analyst expectations

• Adjusted EBITDA for Q4 beat analyst expectations

• Company announced $100 mln share repurchase program

Outlook

• MiMedx estimates 2026 net sales between $340 mln and $360 mln

• Company expects 2026 adjusted EBITDA margin in mid-to-high teens

• Medicare reimbursement changes may impact 2026 revenue

Result Drivers

• WOUND AND SURGICAL GROWTH - Co reported strong double-digit growth in Wound and Surgical sales, driven by new product introductions

• PRODUCT MIX - Favorable product mix contributed to increased gross margins

Company press release: ID:nGNX5dWcKc

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Beat	$118.10 mln	$106.78 mln (6 Analysts)
Q4 Net Income		$15.19 mln
Q4 Adjusted EBITDA	Beat	$29.38 mln	$25.93 mln (4 Analysts)
Q4 Gross Profit		$99.04 mln
Q4 Operating Income		$21.08 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for MiMedx Group Inc is $10.00, about 86.9% above its February 24 closing price of $5.35

• The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.